Is Jisandai (Bingtonsha) included in medical insurance? How to buy specifically?

Epclusa (Epclusa) is a drug used to treat chronic hepatitis C (Hepatitis C), produced by Gilead Sciences (Gilead Sciences). Chronic hepatitis C is a liver disease caused by hepatitis C virus (HCV) infection. If left untreated, it may lead to serious complications such as cirrhosis and liver cancer.

Jisandai (Bingtonsha) has been launched in the country and has been successfully included in the medical insurance system. Patients can now purchase it directly in the country, and the price is about two to three thousand yuan. However, for specific prices and medical insurance reimbursement details, please contact your local hospital pharmacy for detailed consultation. In addition, foreign generic drugs of Jisanda (Bingtonsa), especially the versions produced in Bangladesh and India, are more affordable, ranging from a few hundred to more than a thousand yuan, and their pharmaceutical ingredients are basically the same as domestic original drugs. If you are considering this option, it is recommended that you learn more about and inquire about the relevant regulations and risks.

Gisanda (Bingtonsa) is a compound drug containing two active ingredients: Sofosbuvir (Sofosbuvir) and vimibuvir (Velpatasvir). Sofosbuvir is a nucleoside reverse transcriptase inhibitor that can inhibit the viral RNA replication process, thereby preventing the virus from multiplying. Vimibuvir is an NS5A inhibitor that can block the replication process of the virus in host cells, thereby inhibiting the growth and spread of the virus. The combination of these two ingredients makes Jisandai (Bingtonsha) have a stronger antiviral effect and can effectively remove the hepatitis C virus from the body.

Jisandai (Bingtonsha) is a widely used first-line treatment drug in clinical practice. It is considered to be an efficient and safe treatment option. Through clinical trials and practice, it has been proven that Jisandai (Bingtonsa) can achieve a cure rate of over 95% during the treatment period, and even those patients who have been treated but failed can benefit. Compared with traditional interferon treatment regimens, Gsanda (Bingtonsa) not only has better efficacy, but also has higher tolerability and fewer side effects. This makes it easier for patients to stick with the entire course of treatment and return to health faster.